Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Organisation › Details

iTeos Therapeutics S.A.

iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic (“cold”) tumors. It has licensed its IDO1 program, currently in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). *


Period Start 2012-05-25 splitoff before
  Group iTeos Therapeutics (Group)
  Predecessor Université Catholique de Louvain (UCL)
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 drug target identification
Persons Person Detheux, Michel (iTeos Therapeutics 201205 CEO + Co-founder)
  Person 2 Mertens, Yves (iTeos Therapeutics 201604– CFO before 18y at Aliaxis as CEO + CFO)
Region Region Gosselies
  Country Belgium
  Street 48 Rue Auguste Piccard
Biopark Incubator 2
  City 6041 Gosselies
    Address record changed: 2012-05-25
Basic data Employees B: 11 to 50 (2014-02-10)
    * Document for �About Section�: iTeos Therapeutics S.A.. (7/28/17). "Press Release: iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region". Gosselies.
Record changed: 2020-04-05


Picture [iito] Männer Ballett 650x80px

More documents for iTeos Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80

» top